<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00760461</url>
  </required_header>
  <id_info>
    <org_study_id>0809004202</org_study_id>
    <nct_id>NCT00760461</nct_id>
  </id_info>
  <brief_title>Domperidone in Refractory Gastroparesis</brief_title>
  <official_title>Domperidone in Refractory Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to prescribe oral domperidone for patients with
      gastroparesis who have failed or suffered adverse effects from standard medical therapy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrolled subjects were unable to receive drug from dispensing pharmacy.
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastroparesis Cardinal Symptom Index</measure>
    <time_frame>upon study completion</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Gastroparesis</condition>
  <arm_group>
    <arm_group_label>Domperidone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Domperidone</intervention_name>
    <description>10 mg 4 times daily 20 mg 4 times daily 30 mg 4 times daily</description>
    <arm_group_label>Domperidone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  Age 18 and older

          -  Symptoms or manifestations secondary to motility disorders of the upper GI tract.
             These include gastroparesis, functional dyspepsia, gastroesophageal reflux disease
             that are refractory to standard therapy.

          -  Patients must have a comprehensive evaluation to eliminate other causes of their
             symptoms. This includes a history and physical examination. A recent (within 3 years)
             evaluation of the upper GI tract with either upper endoscopy or upper GI radiographic
             series. Baseline blood tests suggested are electrolytes, magnesium, and prolactin
             level.

          -  Patient has signed informed consent for the administration of domperidone that informs
             the patient of potential adverse events including:

               -  Increased prolactin levels

               -  Breast changes

               -  Extrapyramidal side effects

               -  Cardiac arrhythmias including QT prolongation (increased risk with the drugs
                  listed in the appendix)

        Exclusion Criteria:

          -  History of, or current, arrhythmias including ventricular tachycardia, ventricular
             fibrillation and Torsade des Pointes. Patients with minor forms of ectopy (PACs) are
             not necessarily excluded.

          -  Clinically significant bradycardia, sinus node dysfunction, or heart block. Prolonged
             QTc (QTc&gt;450 milliseconds for males, QTc&gt;470 milliseconds for females)

          -  Clinically significant electrolyte disorders. These include significant hypokalemia,
             hyperkalemia, hypomagnesemia, and hypermagnesemia that cannot be corrected with
             treatment of these electrolyte abnormalities.

          -  Gastrointestinal hemorrhage or obstruction.

          -  Presence of a prolactinoma (prolactin-releasing pituitary tumor).

          -  Pregnant or breast feedings female.

          -  Known allergy to domperidone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anish A Sheth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale Digestive Diseases 40 Temple St, Suite 1A</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2008</study_first_submitted>
  <study_first_submitted_qc>September 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2008</study_first_posted>
  <results_first_submitted>September 15, 2016</results_first_submitted>
  <results_first_submitted_qc>August 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 18, 2017</results_first_posted>
  <last_update_submitted>August 17, 2017</last_update_submitted>
  <last_update_submitted_qc>August 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Domperidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Domperidone</title>
          <description>Domperidone: 10 mg 4 times daily 20 mg 4 times daily 30 mg 4 times daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Domperidone</title>
          <description>Domperidone: 10 mg 4 times daily 20 mg 4 times daily 30 mg 4 times daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age was not collected and summarized.</description>
          <population>Age was not collected and summarized.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Gastroparesis Cardinal Symptom Index</title>
        <time_frame>upon study completion</time_frame>
        <population>Data cannot be summarized or analyzed due to the lack of data being collected on the primary outcome due to the trial being terminated.</population>
        <group_list>
          <group group_id="O1">
            <title>Domperidone</title>
            <description>Domperidone: 10 mg 4 times daily 20 mg 4 times daily 30 mg 4 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Gastroparesis Cardinal Symptom Index</title>
          <population>Data cannot be summarized or analyzed due to the lack of data being collected on the primary outcome due to the trial being terminated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Domperidone</title>
          <description>Domperidone: 10 mg 4 times daily 20 mg 4 times daily 30 mg 4 times daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anish A Sheth M.D</name_or_title>
      <organization>Yale University</organization>
      <phone>203-785-4576</phone>
      <email>anish.sheth@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

